Primary information |
---|
sequence ID | Seq_5316 |
Peptide sequence | MADEAGSEADHEGTHSTKR |
CancerPDF_ID | CancerPDF_ID1227, CancerPDF_ID1328, CancerPDF_ID2363, CancerPDF_ID2367, CancerPDF_ID9752, CancerPDF_ID9754, |
PMID | 21136997,21136997,21136997,21136997,21533267,21533267 |
Protein Name | Fibrinogen alpha,Fibrinogen alpha,Fibrinogen alpha,Fibrinogen alpha,Fibrinogen alpha chain,Fibrinogen alpha chain |
UniprotKB Entry Name | FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN |
Fluid | Serum,Serum,Plasma,Plasma,Serum,Serum |
M/Z | 2027.86029,2043.85521,2027.8603,2043.8552,676.95,682.29 |
Charge | 1,1,1,1,3,3 |
Mass (in Da) | NA,NA,NA,NA,NA,NA |
fdr | NA,NA,NA,NA,NA,NA |
Profiling Technique | LC-MS,LC-MS,LC-MS,LC-MS,LC-MS,LC-MS |
Peptide Identification technique | LC-MS-MS/MS,LC-MS-MS/MS,LC-MS-MS/MS,LC-MS-MS/MS,LC/MS/MS,LC/MS/MS |
Quantification Technique | LC-ESI-MS,LC-ESI-MS,LC-ESI-MS,LC-ESI-MS,Multiple Reaction Monitoring,Multiple Reaction Monitoring |
Labelled/Label Free | Label Free,Label Free,Label Free,Label Free,Label Free,Label Free |
FDR | NA,NA,NA,NA,1.49,1.49 |
CancerPDF_ID | CancerPDF_ID1227, CancerPDF_ID1328, CancerPDF_ID2363, CancerPDF_ID2367, CancerPDF_ID9752, CancerPDF_ID9754, |
p-Value | NA,NA,NA,NA,NA,NA |
Software | MASCOT(v. 2.2.01),MASCOT(v. 2.2.01),MASCOT(v. 2.2.01),MASCOT(v. 2.2.01),MASCOT,MASCOT |
Length | 19,19,19,19,19,19 |
Cancer Type | Colorectal cancer,Colorectal cancer,Normal,Normal,Lung adenocarcinoma,Lung adenocarcinoma |
Database | SwissProt Database,SwissProt Database,SwissProt Database,SwissProt Database,Swissprot Database (57.4),Swissprot Database (57.4) |
Modification | NA,Oxidation of Met,NA,Oxidation of Met,NA,Oxidation |
Number of Patients | 30 patients and 30 healthy controls,30 patients and 30 healthy controls,27 healthy individuals,27 healthy individuals,62 lung adenocarcinoma and 30 healthy control,62 lung adenocarcinoma and 30 healthy control |
Regulation | NA,NA,NA,NA,"Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal","Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" |
Validation | Leave One out Cross validation,Leave One out Cross validation,Leave One out Cross validation,Leave One out Cross validation,MRM-based validation of 19 candidates,MRM-based validation of 19 candidates |
Sensitivity | NA,NA,NA,NA,NA,NA |
Specificity | NA,NA,NA,NA,NA,NA |
Accuracy | NA,NA,NA,NA,NA,NA |
Peptide Atlas | PeptideAtlas |
IEDB | |